Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
3(33%)
Results Posted
0%(0 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_3
3
33%
Ph phase_1
1
11%
Ph phase_2
3
33%

Phase Distribution

1

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
3(42.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

9

all time

Status Distribution
Active(5)
Completed(1)
Terminated(1)
Other(2)

Detailed Status

Active, not recruiting2
Enrolling by invitation2
unknown2
Completed1
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
3
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 23 (42.9%)
Phase 33 (42.9%)

Trials by Status

active_not_recruiting222%
completed111%
enrolling_by_invitation222%
terminated111%
recruiting111%
unknown222%

Recent Activity

3 active trials
Showing 5 of 9
recruitingphase_1

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

NCT03816345
active_not_recruiting

Observational Study Regarding the Combination of Fluoropyrimidine and Bevacizumab in Patients With mCRC

NCT07494578
enrolling_by_invitationphase_2

Modified Capecitabine and Oxaliplatin (mCAPOX) for Patients With GI Malignancies

NCT06648785
active_not_recruitingphase_3

A Trial to Evaluate the Potential Benefit of Adjuvant Chemotherapy for Small Bowel Adenocarcinoma

NCT04257461
enrolling_by_invitation

Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity Study

NCT04260269
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT03816345Phase 1

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Recruiting
NCT07494578

Observational Study Regarding the Combination of Fluoropyrimidine and Bevacizumab in Patients With mCRC

Active Not Recruiting
NCT06648785Phase 2

Modified Capecitabine and Oxaliplatin (mCAPOX) for Patients With GI Malignancies

Enrolling By Invitation
NCT04257461Phase 3

A Trial to Evaluate the Potential Benefit of Adjuvant Chemotherapy for Small Bowel Adenocarcinoma

Active Not Recruiting
NCT04260269

Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity Study

Enrolling By Invitation
NCT04188145Phase 3

A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer

Unknown
NCT03023436Phase 3

Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis

Unknown
NCT00033306Phase 2

BMS-247550 in Treating Patients With Metastatic Colorectal Cancer

Terminated
NCT00399750Phase 2

TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9